Vascular Cognitive Impairment no DementiaPhase 4NCT07700615
Mexidol® Efficacy and Safety in Treatment of VCIND in Older Adults
A Phase 4 study testing Mexidol and Standard Therapy in people with Vascular Cognitive Impairment no Dementia, run by Pharmasoft at 4 sites in Russia.
Trial summary
The primary objective of this study is to evaluate the efficacy of Mexidol® sequential parenteral and oral administration as part of comprehensive therapy in older adults with chronic brain ischemia and vascular cognitive impairment, no dementia (VCIND). Read more about this study
- Who is it for?
- Ages 75 years and older
- Conditions the study is for
- Vascular Cognitive Impairment no Dementia
- What is being tested?
- Mexidol and Standard Therapy
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 4 sitesRussia
- Study dates
- 14 Sep 2025to 5 Nov 2025
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 75 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Signed and dated Informed Consent Form (ICF) by the patient or an impartial witness (in case of physical inability to sign)
- Men and women aged ≥ 75 years at the time of signing the ICF
- Patients with the diagnosis of mild cognitive disorder / vascular cognitive impairment, no dementia (ICD-10 code F06.7) established at least 1 year prior to screening
- A total MoCA score of ≤23 points
- MRI evidence of vascular brain damage obtained within 1 year prior to screening
- Agreement to use highly effective methods of contraception throughout the study and for 3 weeks after study completion. Eligible participants include:
- women of childbearing potential, who have a negative pregnancy test and use the following contraceptive methods: a barrier method (condom or occlusive cap [diaphragm or cervical/vault cap]) or a double-barrier method (condom or occlusive cap [diaphragm or cervical/vault cap] plus spermicide [foam/gel/film/cream/suppository]); women of non-childbearing potential with documented history of hysterectomy, tubal ligation, infertility, or postmenopausal status for more than 1 year;
- fertile men who agree to use barrier contraception; men with documented infertility or prior vasectomy.
Who cannot join
- Hypersensitivity to ethylmethylhydroxypyridine succinate or any other components of the investigational product
- Galactose intolerance, lactase deficiency, or glucose-galactose malabsorption
- Clinically confirmed dementia, defined with the Mini-Mental State Examination score of ≤ 24 points and/or a diagnosis of dementia established according to the Diagnostic and Statistical Manual of mental disorders, Fifth Edition (DSM-5) criteria
- Clinical depression, confirmed by a standardized scale score (e.g., Beck Depression Inventory score of ≥ 29 points) or by a psychiatrist's evaluation
- Chronic heart failure, class III-IV, according to the New York Heart Association (NYHA) Functional Classification at screening
- Uncontrolled arterial hypertension
Show all 24Show fewer
- Uncontrolled diabetes mellitus
- Thyroid dysfunction: hypothyroidism or hyperthyroidism
- Impaired renal function (creatinine clearance calculated by the Cockcroft-Gault formula of less than 50 mL/min) at screening
- Impaired hepatic function (aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≥ 2 times the upper limit of normal (ULN) and/or total bilirubin ≥ 1.5 times the ULN) at screening
- History of Human Immunodeficiency Virus (HIV), syphilis, hepatitis B, and/or hepatitis C
- Severe vitamin B12 deficiency (less than 150 pmol/L)
- Acute infectious diseases (influenza, upper respiratory tract infections, or other) within 4 weeks prior to screening
- Purulent inflammatory diseases of any site
- Use of prohibited medications or other substances that, in the investigator's opinion, may interfere with the study results within 30 days prior to screening, or the anticipated need for such medications during the patient's participation in the study
- Use of medications based on ethylmethylhydroxypyridine succinate, trimetazidine, cytoflavin, or meldonium within 2 months prior to study initiation
- Systemic autoimmune diseases or connective tissue diseases, requiring prior or current treatment with systemic corticosteroids, cytostatics, or other immunosuppressants
- History of malignant neoplasms except for patients with no evidence of disease for the past 5 years, completely cured basal cell carcinoma of the skin, or completely cured carcinoma in situ
- Other severe, decompensated, or unstable somatic diseases (any diseases or conditions that are life-threatening, worsen the patient's prognosis, or prevent participation in a clinical trial)
- Unwillingness or inability of the patient to comply with the Protocol procedures (in the investigator's opinion)
- History of and/or current alcoholism, drug addiction, or substance abuse at screening
- History of schizophrenia, schizoaffective disorder, bipolar disorder, or other psychiatric disorders
- Participation in another clinical trial within 3 months prior to study enrollment
- Any other conditions that, in the investigator's opinion, preclude the patient's inclusion in the study.
Trial locations and contacts
4 sites in 1 country.
Russia4 sites
Ivanovo Regional Clinical Hospital
Ivanovo, 153040
Medinet, LLC
Saint Petersburg, 197136
City Hospital № 40 of Kurortny District
Saint Petersburg, 197706
Vsevolozhsk Clinical Interdistrict Hospital
Vsevolozhsk, 188643
About this study
Official title: Open-label, Randomized, Comparative, Controlled Study of the Efficacy and Safety of Mexidol® Used as an Add-On to Standard Therapy in Older Adults With Vascular Cognitive Impairment, No Dementia
The primary objective of this study is to evaluate the efficacy of Mexidol® sequential parenteral and oral administration as part of comprehensive therapy in older adults with chronic brain ischemia and vascular cognitive impairment, no dementia (VCIND).
Read the detailed description
This is a pilot, open-label, prospective, randomized, comparative, controlled study in parallel groups designed to evaluate the efficacy and safety of sequential Mexidol® therapy used in addition to standard therapy in older adults with chronic brain ischemia and vascular cognitive impairment, no dementia (VCIND).
The study included 120 participants randomized into two groups:
- Group 1 received standard therapy combined with Mexidol® solution (500 mg once daily, IV infusion) for the first 5 days, followed by Mexidol® FORTE 250 tablets (250 mg three times daily) for 60 days.
- Group 2 received standard therapy only.
Within each treatment group, a pre-specified subgroup analysis was performed based on the presence or absence of frailty, followed by a comparative analysis of the secondary outcome measures for each subgroup.
- Being tested
- Mexidol, Standard Therapy
- Keywords
- Vascular Cognitive Impairment, Pre-Dementia Vascular Cognitive Impairment, vascular cognitive impairment no dementia, Mild Cognitive Impairment, Pre-Dementia, VCI, MCI, Neuroprotection, Mexidol, Ethylmethylhydroxypyridine Succinate, Antioxidants, Sequential Therapy, Elderly, Geriatric Patients, VCIND, Subgroup Analysis, Older Adults
- Medical subject headings
- Cognitive Dysfunction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MexidolDrug
In addition to standard therapy, Mexidol sequential therapy was administered in two phases:
- Days 1 to 5: Intravenous (IV) infusion of 10 mL (500 mg) once daily, diluted in 100-150 mL of 0.9% sodium chloride solution. Infusion rate: 40-60 drops per minute.
- Days 6 to 65: Oral administration of Mexidol® FORTE 250 mg tablets, 1 tablet 3 times daily (750 mg total daily dose) for 60 consecutive days.
Standard TherapyOther
Standard background therapy administered in accordance with institutional protocols and applicable clinical guidelines, including cognitive training.
| Study group | Role | What they receive |
|---|---|---|
| Mexidol® + Standard Therapy | Experimental | Patients receive standard background therapy combined with sequential parenteral and oral administration of Mexidol® for a total duration of 65 days. Receives: Drug: Mexidol |
| Standard Therapy Alone | Active comparator | Patients receive standard background therapy alone. Receives: Other: Standard Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in the Montreal Cognitive Assessment (MoCA) Total Score at Visit 4 compared to Visit 0 by treatment groups
The Montreal Cognitive Assessment (MoCA) is a 30-point validated scale that covers multiple cognitive domains including spatiotemporal orientation, sustained attention, visuospatial function, executive function, verbal memory, language, naming, and abstract thinking [30-point scale: min value 0, max value 30, higher scores mean a better outcome].
Measured: Visit 0 (Baseline, Day -4 to Day 0) and Visit 4 (Day 65±2 days)
Secondary outcomes (19)
Change in the Montreal Cognitive Assessment (MoCA) Total Score at Visit 2 compared to Visit 1
The Montreal Cognitive Assessment (MoCA) is a 30-point validated scale that covers multiple cognitive domains including spatiotemporal orientation, sustained attention, visuospatial function, executive function, verbal memory, language, naming, and abstract thinking [30-point scale: min value 0, max value 30, higher scores mean a better outcome].
Note: Per protocol, the MoCA assessment is performed at Visit 0 (Screening). For patients where Visit 1 (Randomization) and Visit 0 do not coincide, the screening data are used as the baseline values for Visit 1.
Measured: Visit 1 / Visit 0 (Baseline, Day -4 to Day 1) and Visit 2 (Day 5)
Change in the Clinical Global Impression (CGI) Scale Scores at Visit 2 Compared to Visit 1, Including Severity of Illness, Global Clinical Change, and Efficacy Index
The Clinical Global Impression (CGI) scale is a 3-item observer-rated scale used to evaluate illness severity, global improvement or change, and treatment response. It consists of three independent subscales, each rated separately: CGI-Severity (CGI-S) rates the severity of illness on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients); CGI-Improvement (CGI-I) rates the patient's change over time on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse); CGI-Efficacy Index is a 4x4 rating scale that assesses the therapeutic effect and treatment-related adverse events. Scores range from 00 (not assessed) or 01 (marked improvement and no side effects) to 16 (unchanged or worse and side effects outweigh the therapeutic effects). A lower score reflects a better therapeutic index.
Measured: Visit 1 (Day 1) and Visit 2 (Day 5)
Change in the Beck Anxiety Inventory (BAI) Total Score at Visit 2 compared to Visit 1
The Beck Anxiety Inventory (BAI) consists of 21 self-report items (scored on a 4-point scale) used to assess the severity of physical and cognitive anxiety symptoms during the past week. Total scores range from 0 to 63: minimal anxiety (0-7), mild anxiety (8-15), moderate anxiety (16-25), and severe anxiety (26-63). [Scale range: 0 to 63; lower scores indicate a better outcome].
Measured: Visit 1 (Day 1) and Visit 2 (Day 5)
Change in the Mini-Mental State Examination (MMSE) Total Score at Visit 4 compared to Visit 0
The Mini-Mental State Examination (MMSE) is a 30-point questionnaire of global cognitive status that assesses five key areas of cognitive function: orientation, registration, attention and calculation, recall, and language. Total scores range from 0 to 30, with higher scores indicating better cognition. A score of 24 or more indicates normal cognition. Scores below 24 indicate cognitive impairment, categorized as mild (19-23 points), moderate (10-18 points), or severe (≤9 points) [30-point scale: min value 0, max value 30, higher scores mean a better outcome].
Measured: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the Lawton Instrumental Activities of Daily Living (IADL) Scale Total Score at Visit 4 compared to Visit 1
The Lawton Instrumental Activities of Daily Living (IADL) Scale is an 8-item instrument used to assess independent living skills and complex occupational performance. The scale evaluates 8 functional domains: ability to use telephone, shopping, food preparation, housekeeping, laundry, mode of transportation, responsibility for own medications, and ability to handle finances. Each item is scored as either 0 (dependent) or 1 (independent). The total score is calculated as the sum of all 8 domains ranging from 0 to 8. A score of 0 represents low functioning (maximum dependence) and a score of 8 represents high functioning (full independence) [Scale range: 0 to 8; higher scores indicate a better outcome].
Measured: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the Barthel Index (BI) for Activities of Daily Living Total Score at Visit 4 compared to Visit 1
The Barthel Index (BI) for Activities of Daily Living is a validated 10-item clinician- or caregiver-reported rating scale used to assess a patient's performance and level of independence in basic activities of daily living (ADL) and mobility. The index evaluates 10 functional domains: feeding, bathing, grooming, dressing, bowels, bladder, toilet use, transfers, mobility, and stairs. Items are scored in increments of 5. The total score is calculated as the sum of all 10 items, ranging from 0 to 100. A score of 0 represents complete dependence, while a score of 100 represents complete independence. [Scale range: 0 to 100; higher scores indicate a better outcome].
Measured: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the Short Physical Performance Battery (SPPB) Total Score at Visit 4 compared to Visit 1
The Short Physical Performance Battery (SPPB) is a standardized assessment tool used to evaluate lower extremity function and mobility in older adults. It consists of three objective subtests designed to mimic everyday physical demands: a 4-meter walk to assess gait speed, a repeated chair stand test (rising from a seated position 5 times) to assess lower limb strength, and three 10-second static balance tests in different foot positions (side-by-side, semi-tandem, and tandem). Each of the three subtests is scored from 0 to 4, resulting in a total summary score ranging from 0 to 12. Lower scores indicate poorer physical function and higher disability, while higher scores indicate better lower extremity performance and functional independence. [Scale range: 0 to 12; higher scores indicate a better outcome].
Measured: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the Digit Symbol Substitution Test (DSST) Total Score at Visit 4 compared to Visit 0
The Digit Symbol Substitution Test (DSST) is used to measure attention, processing speed and executive function. It is a pencil and paper test of psychomotor performance in which the subject is given a key grid of numbers and matching symbols and a test section with numbers and empty boxes. The test consists of filling as many empty boxes as possible with a symbol matching each number. The score is the number of correct number-symbol matches achieved in 90 s. Scores range from 0 to 100, with higher scores indicating higher cognitive function.
Measured: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the Multidimensional Fatigue Inventory (MFI-20) Total Score at Visit 4 compared to Visit 1
The Multidimensional Fatigue Inventory (MFI-20) is a 20-item self-administered questionnaire designed to measure fatigue in five 4-item subscales: General fatigue, Physical fatigue, Reduced activity, Reduced motivation and Mental fatigue. MFI-20 has an even proportion of positively and negatively worded items that are rated on a 5-point Likert scale. Subscale scores (range 4-20) are calculated as the sum of item ratings and a total fatigue score (range 20-100) is calculated as the sum of subscale scores. Higher scores indicate a higher level of fatigue.
Measured: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the Beck Anxiety Inventory (BAI) Total Score at Visit 4 compared to Visit 1
The Beck Anxiety Inventory (BAI) consists of 21 self-report items (scored on a 4-point scale) used to assess the severity of physical and cognitive anxiety symptoms during the past week. Total scores range from 0 to 63: minimal anxiety (0-7), mild anxiety (8-15), moderate anxiety (16-25), and severe anxiety (26-63). [Scale range: 0 to 63; lower scores indicate a better outcome].
Measured: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the Tinetti Gait and Balance Test Total Score at Visit 4 compared to Visit 1
The Tinetti Gait and Balance Test is a clinical test for the assessment of balance and gait. It has a gait score and a balance score using a 3-point ordinal scale of 0, 1 and 2. Gait is scored over 12 and balance is scored over 16 totaling 28. The lower the score on the Tinetti test, the higher the risk of falling. Tinetti test score equal or less than 18 shows high risk of fall, 19-23 scores show moderate risk of fall, and score equal or higher than 24 shows low risk of fall. Min value is 0, max value is 28, higher scores mean a better outcome.
Measured: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the 36-Item Short Form Survey (SF-36) Total Score at Visit 4 compared to Visit 1
The 36-Item Short Form Health Survey (SF-36) consists of eight scales yielding two summary measures: physical and mental health. To score the SF-36, scales are standardized with a scoring algorithm or by the SF-36v2 scoring software to obtain a score ranging from 0 to 100. Higher scores indicate a better health status, and a mean score of 50 represents a normative value for all scales. [Scale range: 0 to 100; higher scores indicate a better outcome].
Measured: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the Clinical Global Impression (CGI) Scale Scores at Visit 4 Compared to Visit 1, Including Severity of Illness, Global Clinical Change, and Efficacy Index
The Clinical Global Impression (CGI) scale is a 3-item observer-rated scale used to evaluate illness severity, global improvement or change, and treatment response. It consists of three independent subscales, each rated separately: CGI-Severity (CGI-S) rates the severity of illness on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients); CGI-Improvement (CGI-I) rates the patient's change over time on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse); CGI-Efficacy Index is a 4x4 rating scale that assesses the therapeutic effect and treatment-related adverse events. Scores range from 00 (not assessed) or 01 (marked improvement and no side effects) to 16 (unchanged or worse and side effects outweigh the therapeutic effects). A lower score reflects a better therapeutic index.
Measured: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the Morse Fall Scale (MFS) Total Score at Visit 4 compared to Visit 1
The Morse Fall Scale (MFS) is a validated 6-item clinician-reported tool used to assess a participant's risk of falling. It evaluates six variables: history of falling, secondary diagnosis, ambulatory aid, intravenous therapy, gait/transferring, and mental status. The total score is calculated as the sum of all items, ranging from 0 to 125. Scores are stratified into low risk (0-24), moderate risk (25-44), and high risk (≥45) of falling. [Scale range: 0 to 125; higher scores indicate a worse outcome].
Measured: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the Falls Risk Self-Assessment Scale Total Score at Visit 4 compared to Visit 1
The Falls Risk Self-Assessment Scale is a 12-item self-administered questionnaire used to evaluate a participant's perceived risk of falling. For each question, a "no" answer is scored as 0 points, while a "yes" answer is scored as either 1 or 2 points, depending on the item weight. The total score is calculated as the sum of all 12 items. Total scores are interpreted as follows: a score of less than 4 points indicates a low risk of falling, and a score of 4 or more points indicates a high risk of falling. [Scale range: 0 to 14; lower scores indicate a better outcome].
Measured: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the Insomnia Severity Index (ISI) Total Score at Visit 4 compared to Visit 1
The Insomnia Severity Index (ISI) is a 7-item self-administered instrument used to assess the nature, severity, and impact of sleep disturbances experienced over the past 2 weeks. Individual items are rated on a 5-point Likert scale (0 to 4), with the total score calculated as the sum of all 7 items, ranging from 0 to 28. Total scores are interpreted as follows: no clinically significant insomnia (0-7 points), subthreshold insomnia (8-14 points), clinical insomnia of moderate severity (15-21 points), and severe clinical insomnia (22-28 points). [Scale range: 0 to 28; lower scores indicate a better outcome].
Measured: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in Time to Complete the Trail Making Test Part A (TMT-A) at Visit 4 compared to Visit 1
The Trail Making Test Part A (TMT-A) is a neuropsychological instrument used to assess visual search, scanning, speed of processing, and executive function. Participants are required to connect a set of 25 encircled numbers in numerical order as rapidly as possible. Performance is scored based on the total time taken to complete the task, where each second equals 1 point. A higher score (longer completion time) indicates cognitive impairment, while a lower score indicates better cognitive performance and faster processing speed. [Scale range: not applicable; lower scores indicate a better outcome].
Measured: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in Time to Complete the Trail Making Test Part B (TMT-B) at Visit 4 compared to Visit 1
The Trail Making Test Part B (TMT-B) is a neuropsychological instrument used to assess visual search, scanning, speed of processing, cognitive flexibility, and executive function. Participants are required to connect a set of 25 encircled numbers and letters, alternating between numerical and alphabetical order (e.g., 1-A-2-B) as rapidly as possible. Performance is scored based on the total time taken to complete the task, where each second equals 1 point. A higher score (longer completion time) indicates cognitive impairment, while a lower score indicates better cognitive performance. [Scale range: not applicable; lower scores indicate a better outcome].
Measured: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Assessment of Safety
Total number of adverse events (AEs), stratified by severity and frequency; Incidence of adverse drug reactions (ADRs); Incidence of serious adverse events (SAEs) related to the investigational product; Proportion of participants with at least one reported AE; Proportion of participants who discontinued treatment due to AEs.
Note: All clinically significant deviations in patient health status (based on physical examination, laboratory, and instrumental assessments) from baseline screening data and reference ranges were recorded as adverse events. Adverse medical events detected during the screening period were classified as medical history (pre-existing/concomitant conditions).
Measured: From Day 1 (Visit 1) to Day 65 (Visit 4)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2026
- Study start14 Sep 2025
- Primary completion5 Nov 2025
- Study completion5 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vascular Cognitive Impairment no DementiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 120 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pharmasoft
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07700615
- Sponsor's protocol ID
- PHS-PS-REAB-002-MEX-SOL-TAB
- Status last verified
- Jul 2026
- First submitted
- 7 Jul 2026
- Last updated
- 14 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Open-label, Randomized, Comparative, Controlled Study of the Efficacy and Safety of Mexidol® Used as an Add-On to Standard Therapy in Older Adults With Vascular Cognitive Impairment, No Dementia
- ClinicalTrials.gov ID
- NCT07700615
- Acronym / sponsor ID
- PHS-PS-REAB-002-MEX-SOL-TAB
- Keywords
- Vascular Cognitive Impairment, Pre-Dementia Vascular Cognitive Impairment, vascular cognitive impairment no dementia, Mild Cognitive Impairment, Pre-Dementia, VCI, MCI, Neuroprotection
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 120 participants (actual)
- Lead sponsor
- PharmasoftIndustry (pharma, biotech, devices)
- Study start
- 14 Sep 2025 (actual)
- Primary completion
- 5 Nov 2025 (actual)
- Study completion
- 5 Nov 2025 (actual)
- First posted
- 14 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is to evaluate the efficacy of Mexidol® sequential parenteral and oral administration as part of comprehensive therapy in older adults with chronic brain ischemia and vascular cognitive impairment, no dementia (VCIND).
Detailed description
This is a pilot, open-label, prospective, randomized, comparative, controlled study in parallel groups designed to evaluate the efficacy and safety of sequential Mexidol® therapy used in addition to standard therapy in older adults with chronic brain ischemia and vascular cognitive impairment, no dementia (VCIND).
The study included 120 participants randomized into two groups:
- Group 1 received standard therapy combined with Mexidol® solution (500 mg once daily, IV infusion) for the first 5 days, followed by Mexidol® FORTE 250 tablets (250 mg three times daily) for 60 days.
- Group 2 received standard therapy only.
Within each treatment group, a pre-specified subgroup analysis was performed based on the presence or absence of frailty, followed by a comparative analysis of the secondary outcome measures for each subgroup.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Mexidol® + Standard Therapy | Experimental | Drug: MexidolPatients receive standard background therapy combined with sequential parenteral and oral administration of Mexidol® for a total duration of 65 days. |
| Standard Therapy Alone | Active comparator | Other: Standard TherapyPatients receive standard background therapy alone. |
Who may qualify
- Ages
- 75 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (8 listed)
- Signed and dated Informed Consent Form (ICF) by the patient or an impartial witness (in case of physical inability to sign)
- Men and women aged ≥ 75 years at the time of signing the ICF
- Patients with the diagnosis of mild cognitive disorder / vascular cognitive impairment, no dementia (ICD-10 code F06.7) established at least 1 year prior to screening
- A total MoCA score of ≤23 points
- MRI evidence of vascular brain damage obtained within 1 year prior to screening
Key exclusion criteria (24 listed)
- Hypersensitivity to ethylmethylhydroxypyridine succinate or any other components of the investigational product
- Galactose intolerance, lactase deficiency, or glucose-galactose malabsorption
- Clinically confirmed dementia, defined with the Mini-Mental State Examination score of ≤ 24 points and/or a diagnosis of dementia established according to the Diagnostic and Statistical Manual of mental disorders, Fifth Edition (DSM-5) criteria
- Clinical depression, confirmed by a standardized scale score (e.g., Beck Depression Inventory score of ≥ 29 points) or by a psychiatrist's evaluation
- Chronic heart failure, class III-IV, according to the New York Heart Association (NYHA) Functional Classification at screening
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MexidolIn addition to standard therapy, Mexidol sequential therapy was administered in two phases: * Days 1 to 5: Intravenous (IV) infusion of 10 mL (500 mg) once daily, diluted in 100-150 mL of 0.9% sodium chloride solution. Infusion rate: 40-60 drops per minute. * Days 6 to 65: Oral administration of Mexidol® FORTE 250 mg tablets, 1 tablet 3 times daily (750 mg total daily dose) for 60 consecutive days. | Drug | Mexidol® + Standard Therapy |
| Standard TherapyStandard background therapy administered in accordance with institutional protocols and applicable clinical guidelines, including cognitive training. | Other | Standard Therapy Alone |
Primary outcome
Change in the Montreal Cognitive Assessment (MoCA) Total Score at Visit 4 compared to Visit 0 by treatment groups
Time frame: Visit 0 (Baseline, Day -4 to Day 0) and Visit 4 (Day 65±2 days)
The Montreal Cognitive Assessment (MoCA) is a 30-point validated scale that covers multiple cognitive domains including spatiotemporal orientation, sustained attention, visuospatial function, executive function, verbal memory, language, naming, and abstract thinking [30-point scale: min value 0, max value 30, higher scores mean a better outcome].
19 secondary outcomes
Change in the Montreal Cognitive Assessment (MoCA) Total Score at Visit 2 compared to Visit 1
Time frame: Visit 1 / Visit 0 (Baseline, Day -4 to Day 1) and Visit 2 (Day 5)
Change in the Clinical Global Impression (CGI) Scale Scores at Visit 2 Compared to Visit 1, Including Severity of Illness, Global Clinical Change, and Efficacy Index
Time frame: Visit 1 (Day 1) and Visit 2 (Day 5)
Change in the Beck Anxiety Inventory (BAI) Total Score at Visit 2 compared to Visit 1
Time frame: Visit 1 (Day 1) and Visit 2 (Day 5)
Change in the Mini-Mental State Examination (MMSE) Total Score at Visit 4 compared to Visit 0
Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the Lawton Instrumental Activities of Daily Living (IADL) Scale Total Score at Visit 4 compared to Visit 1
Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the Barthel Index (BI) for Activities of Daily Living Total Score at Visit 4 compared to Visit 1
Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the Short Physical Performance Battery (SPPB) Total Score at Visit 4 compared to Visit 1
Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the Digit Symbol Substitution Test (DSST) Total Score at Visit 4 compared to Visit 0
Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the Multidimensional Fatigue Inventory (MFI-20) Total Score at Visit 4 compared to Visit 1
Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the Beck Anxiety Inventory (BAI) Total Score at Visit 4 compared to Visit 1
Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the Tinetti Gait and Balance Test Total Score at Visit 4 compared to Visit 1
Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the 36-Item Short Form Survey (SF-36) Total Score at Visit 4 compared to Visit 1
Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the Clinical Global Impression (CGI) Scale Scores at Visit 4 Compared to Visit 1, Including Severity of Illness, Global Clinical Change, and Efficacy Index
Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the Morse Fall Scale (MFS) Total Score at Visit 4 compared to Visit 1
Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the Falls Risk Self-Assessment Scale Total Score at Visit 4 compared to Visit 1
Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in the Insomnia Severity Index (ISI) Total Score at Visit 4 compared to Visit 1
Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in Time to Complete the Trail Making Test Part A (TMT-A) at Visit 4 compared to Visit 1
Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Change in Time to Complete the Trail Making Test Part B (TMT-B) at Visit 4 compared to Visit 1
Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)
Assessment of Safety
Time frame: From Day 1 (Visit 1) to Day 65 (Visit 4)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Vascular Cognitive Impairment no Dementia
Recruiting
Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia
Cerebrovascular Disorders
Recruiting
Exercise as a Primer for Brain Stimulation in Vascular Cognitive Impairment No Dementia (VCIND)
Vascular Cognitive Impairment, Mild Cognitive Impairment
Not yet recruiting
Language Intervention Training for Cognitive Protection in High-risk Cardio-Cerebrovascular Elderly Population
Vascular Cognitive Impairment No Dementia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Mexidol and Standard Therapy in people with Vascular Cognitive Impairment no Dementia, run by Pharmasoft at 4 sites in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in the Montreal Cognitive Assessment (MoCA) Total Score at Visit 4 compared to Visit 0 by treatment groups (time frame: Visit 0 (Baseline, Day -4 to Day 0) and Visit 4 (Day 65±2 days)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2026.